<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01569815</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696A2204</org_study_id>
    <secondary_id>2007-005480-96</secondary_id>
    <nct_id>NCT01569815</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function</brief_title>
  <official_title>An Open Label, Parallel-group Study to Determine Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Mild and Moderate Renal Impairment Compared to Matched Healthy Subjects With Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the multiple dose pharmacokinetics of LCZ696 and
      its metabolites in subjects with mild to moderate renal impairment and to evaluate the safety
      of LCZ696 in this population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Reach Maximum Peak Plasma Concentration (Tmax) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)</measure>
    <time_frame>Day 1 and day 5</time_frame>
    <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Peak Plasma Concentration (Cmax) Observed After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)</measure>
    <time_frame>Day 1, day 5</time_frame>
    <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC0-24) From Time Zero to 24- Hour Post-dose (Day 1), and After Multiple Dose Administration (Day 5)</measure>
    <time_frame>Day 1 and day 5</time_frame>
    <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Half-life (t1/2) After Multiple Dose (Day 5) Administration</measure>
    <time_frame>Day 5</time_frame>
    <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic Clearance From Plasma Following Extravascular Administration (CL/F) After Multiple Dose Administration (Day 5)</measure>
    <time_frame>Day 5</time_frame>
    <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Ratio (Racc) After Multiple Dose Administration (Day 5)</measure>
    <time_frame>Day 5</time_frame>
    <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance From Plasma (CLr) After Multiple Dose Administration (Day 5)</measure>
    <time_frame>Day 5</time_frame>
    <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of Drug Excreted Into the Urine From Time Zero to 24-hours Post-dose (Ae0-24) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)</measure>
    <time_frame>Day 1 and Day 5</time_frame>
    <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean 24-hours Sodium Clearance From Baseline to Day 7</measure>
    <time_frame>From baseline to Day 7</time_frame>
    <description>Sodium clearance will be measured in urine from baseline until Day 7</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Mild and Moderate Renal Impairment</condition>
  <arm_group>
    <arm_group_label>LCZ696 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCZ696 400 mg once daily for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <description>LCZ696 400 mg once daily</description>
    <arm_group_label>LCZ696 400 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male, and female subjects of non-child bearing potential,

          2. Subjects were to weigh at least 50 kg to participate in the study,

          3. and body mass index &lt; 40 kg/m2

          4. Subjects were able to communicate well with the investigator, to understand and comply
             with the requirements of the study;

          5. Subjects were able to understand and sign the written informed consent;

        For renal insufficient subjects:

          1. stable renal disease without evidence of renal progressive

               -  mild renal function: calculated CrCl of 50-≤80 mL/min

               -  moderate renal function: calculated CrCl of 30-&lt;50 mL/min

          2. Vital signs:

               -  oral body temperature between 35.0-37.8 °C

               -  systolic blood pressure, 95-180 mm Hg

               -  diastolic blood pressure, 60-110 mm Hg

               -  pulse rate, 54-95 bpm

        For healthy subjects only

          1. A serum creatinine with a calculated CrCl of &gt;80 mL/min

          2. Vital signs:

               -  oral body temperature between 35.0-37.2 °C

               -  systolic blood pressure, 95-140 mm Hg

               -  diastolic blood pressure, 60-100 mm Hg

               -  pulse rate, 45-90 bpm

        Exclusion Criteria:

          1. Current use of ACE inhibitors, valsartan, and drugs that were known as CYP2C9
             substrates, potassium-sparing diuretics;

          2. Smokers;

          3. History of renal transplant at any time in the past and on immunosuppressant therapy;

          4. Dialysis patients;

          5. Medical history of clinically significant ECG abnormalities or a family history of a
             prolonged QT-interval syndrome;

          6. Any surgical or medical condition which may significantly alter the absorption,
             distribution, metabolism or excretion of any drug substance; Other protocol defined
             inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117292</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2012</study_first_posted>
  <results_first_submitted>July 30, 2015</results_first_submitted>
  <results_first_submitted_qc>July 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 27, 2015</results_first_posted>
  <last_update_submitted>September 25, 2015</last_update_submitted>
  <last_update_submitted_qc>September 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Impairment,</keyword>
  <keyword>LCZ696</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mild Renal Impaired</title>
          <description>LCZ696 400 mg once daily for 5 days</description>
        </group>
        <group group_id="P2">
          <title>Mild Renal Impaired Matched Healthy Subjects</title>
          <description>LCZ696 400 mg once daily for 5 days</description>
        </group>
        <group group_id="P3">
          <title>Moderate Renal Impaired Subjects</title>
          <description>LCZ696 400 mg once daily for 5 days</description>
        </group>
        <group group_id="P4">
          <title>Moderate Renal Impaired Matched Healthy Subjects</title>
          <description>LCZ696 400 mg once daily for 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mild Renal Impaired Subjects</title>
          <description>LCZ696 400 mg once daily for 5 days</description>
        </group>
        <group group_id="B2">
          <title>Mild Renal Impaired Matched Healthy Subjects</title>
          <description>LCZ696 400 mg once daily for 5 days</description>
        </group>
        <group group_id="B3">
          <title>Moderate Renal Impaired Subjects</title>
          <description>LCZ696 400 mg once daily for 5 days</description>
        </group>
        <group group_id="B4">
          <title>Moderate Renal Impaired Matched Healthy Subjects</title>
          <description>LCZ696 400 mg once daily for 5 days</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.0" spread="10.88"/>
                    <measurement group_id="B2" value="50.6" spread="11.70"/>
                    <measurement group_id="B3" value="54.5" spread="8.33"/>
                    <measurement group_id="B4" value="53.9" spread="8.95"/>
                    <measurement group_id="B5" value="52.5" spread="9.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Peak Plasma Concentration (Tmax) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)</title>
        <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
        <time_frame>Day 1 and day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild Renal Impaired Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impaired Matched Healthy Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impaired Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Moderate Renal Impaired Matched Healthy Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Peak Plasma Concentration (Tmax) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)</title>
          <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHU377 day 1, single dose of LCZ696 400 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.5" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.5" upper_limit="1.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.5" upper_limit="4.0"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AHU377 day 5, multiple doses of LCZ696 400 mg Q.D.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.5" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.5" upper_limit="1.0"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0.5" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657 day 1, single dose of LCZ696 400 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="2" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="O3" value="3" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="O4" value="3" lower_limit="2" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657 day 5, multiple doses of LCZ696 400 mg Q.D.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="O3" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O4" value="3" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 day 1, single dose of LCZ696 400 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="O2" value="2" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O3" value="2" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O4" value="2" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 day 5,multiple doses LCZ696 400 mg Q.D.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O3" value="2" lower_limit="2" upper_limit="2"/>
                    <measurement group_id="O4" value="2" lower_limit="2" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Peak Plasma Concentration (Cmax) Observed After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)</title>
        <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
        <time_frame>Day 1, day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild Renal Impaired Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impaired Matched Healthy Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impaired Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Moderate Renal Impaired Matched Healthy Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Peak Plasma Concentration (Cmax) Observed After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)</title>
          <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHU377 day 1, single dose of LCZ696 400 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4220" spread="1514"/>
                    <measurement group_id="O2" value="3995" spread="1368"/>
                    <measurement group_id="O3" value="3539" spread="1414"/>
                    <measurement group_id="O4" value="3743" spread="1486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AHU377 day 5, multiple doses of LCZ696 400 mg Q.D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3904" spread="1780"/>
                    <measurement group_id="O2" value="3125" spread="1729"/>
                    <measurement group_id="O3" value="4109" spread="1739"/>
                    <measurement group_id="O4" value="3756" spread="1644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657 day 1, single dose of LCZ696 400 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17575" spread="3500"/>
                    <measurement group_id="O2" value="15200" spread="2958"/>
                    <measurement group_id="O3" value="18175" spread="3210"/>
                    <measurement group_id="O4" value="16000" spread="2451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657 day 5, multiple doses of LCZ696 400 mg Q.D.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27150" spread="6449"/>
                    <measurement group_id="O2" value="16838" spread="3063"/>
                    <measurement group_id="O3" value="28988" spread="7861"/>
                    <measurement group_id="O4" value="18375" spread="3215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 day 1, single dose of LCZ696 400 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7208" spread="3606"/>
                    <measurement group_id="O2" value="6215" spread="1588"/>
                    <measurement group_id="O3" value="6178" spread="2584"/>
                    <measurement group_id="O4" value="7981" spread="2059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 day 5,multiple dose LCZ696 400 mg Q.D.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6873" spread="4348"/>
                    <measurement group_id="O2" value="6275" spread="2242"/>
                    <measurement group_id="O3" value="7665" spread="2612"/>
                    <measurement group_id="O4" value="8006" spread="3895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve (AUC0-24) From Time Zero to 24- Hour Post-dose (Day 1), and After Multiple Dose Administration (Day 5)</title>
        <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
        <time_frame>Day 1 and day 5</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Mild Renal Impaired Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impaired Matched Healthy Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impaired Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Moderate Renal Impaired Matched Healthy Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve (AUC0-24) From Time Zero to 24- Hour Post-dose (Day 1), and After Multiple Dose Administration (Day 5)</title>
          <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
          <population>FAS</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHU377 day 1, single dose of LCZ696 400 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5679" spread="1864"/>
                    <measurement group_id="O2" value="5396" spread="1197"/>
                    <measurement group_id="O3" value="5359" spread="2287"/>
                    <measurement group_id="O4" value="5963" spread="2559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AHU377 day 5, multiple doses of LCZ696 400 mg Q.D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5656" spread="1859"/>
                    <measurement group_id="O2" value="5221" spread="1162"/>
                    <measurement group_id="O3" value="5283" spread="2267"/>
                    <measurement group_id="O4" value="5716" spread="1849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657 day 1, single dose of LCZ696 400 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226159" spread="49810"/>
                    <measurement group_id="O2" value="144500" spread="15533"/>
                    <measurement group_id="O3" value="262422" spread="52115"/>
                    <measurement group_id="O4" value="154871" spread="31504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657 day 5, multiple dose of LCZ696 400 mg Q.D.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="371331" spread="99259"/>
                    <measurement group_id="O2" value="172335" spread="21925"/>
                    <measurement group_id="O3" value="437134" spread="146930"/>
                    <measurement group_id="O4" value="190598" spread="44468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 day 1, single dose of LCZ696 400 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62411" spread="43846"/>
                    <measurement group_id="O2" value="40658" spread="11401"/>
                    <measurement group_id="O3" value="47135" spread="21560"/>
                    <measurement group_id="O4" value="50220" spread="19732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 day 5,multiple dose LCZ696 400 mg Q.D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59223" spread="50669"/>
                    <measurement group_id="O2" value="39517" spread="17227"/>
                    <measurement group_id="O3" value="51777" spread="18967"/>
                    <measurement group_id="O4" value="56460" spread="31412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Elimination Half-life (t1/2) After Multiple Dose (Day 5) Administration</title>
        <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
        <time_frame>Day 5</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Mild Renal Impaired Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impaired Matched Healthy Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impaired Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Moderate Renal Impaired Matched Healthy Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-life (t1/2) After Multiple Dose (Day 5) Administration</title>
          <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
          <population>FAS</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHU377 day 5, multiple doses of LCZ696 400 mg Q.D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.6"/>
                    <measurement group_id="O2" value="4.7" spread="6.0"/>
                    <measurement group_id="O3" value="2.9" spread="2.3"/>
                    <measurement group_id="O4" value="1.8" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657 day 5, multiple dose of LCZ696 400 mg Q.D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" spread="8.3"/>
                    <measurement group_id="O2" value="12.6" spread="1.7"/>
                    <measurement group_id="O3" value="23.7" spread="5.0"/>
                    <measurement group_id="O4" value="12.3" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 day 5,multiple dose LCZ696 400 mg Q.D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" spread="4.7"/>
                    <measurement group_id="O2" value="14.5" spread="3.7"/>
                    <measurement group_id="O3" value="22.7" spread="14.6"/>
                    <measurement group_id="O4" value="12.4" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Systemic Clearance From Plasma Following Extravascular Administration (CL/F) After Multiple Dose Administration (Day 5)</title>
        <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
        <time_frame>Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild Renal Impaired Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impaired Matched Healthy Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impaired Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Moderate Renal Impaired Matched Healthy Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Clearance From Plasma Following Extravascular Administration (CL/F) After Multiple Dose Administration (Day 5)</title>
          <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
          <units>mL/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHU377 day 5, multiple doses of LCZ696 400 mg Q.D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38261" spread="14002"/>
                    <measurement group_id="O2" value="39137" spread="10451"/>
                    <measurement group_id="O3" value="42704" spread="17238"/>
                    <measurement group_id="O4" value="37902" spread="14487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657 day 5, multiple dose of LCZ696 400 mg Q.D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">LBQ657 is a metabolite of AHU377, and hence LBQ657 CL/F values are not relevant.</measurement>
                    <measurement group_id="O2" value="NA">LBQ657 is a metabolite of AHU377, and hence LBQ657 CL/F values are not relevant.</measurement>
                    <measurement group_id="O3" value="NA">LBQ657 is a metabolite of AHU377, and hence LBQ657 CL/F values are not relevant.</measurement>
                    <measurement group_id="O4" value="NA">LBQ657 is a metabolite of AHU377, and hence LBQ657 CL/F values are not relevant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 day 5,multiple dose LCZ696 400 mg Q.D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4636" spread="17080"/>
                    <measurement group_id="O2" value="6499" spread="3876"/>
                    <measurement group_id="O3" value="4929" spread="3260"/>
                    <measurement group_id="O4" value="5988" spread="6568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accumulation Ratio (Racc) After Multiple Dose Administration (Day 5)</title>
        <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
        <time_frame>Day 5</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Mild Renal Impaired Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impaired Matched Healthy Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impaired Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Moderate Renal Impaired Matched Healthy Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio (Racc) After Multiple Dose Administration (Day 5)</title>
          <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
          <population>FAS</population>
          <units>Ratio (AUC0-24, day 5)/(AUC0-24, day 1)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHU377 day 5, multiple dose of LCZ696 400 mg Q.D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.1"/>
                    <measurement group_id="O2" value="1.0" spread="0.2"/>
                    <measurement group_id="O3" value="1.0" spread="0.2"/>
                    <measurement group_id="O4" value="1.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657 day 5, multiple dose of LCZ696 400 mg Q.D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.27"/>
                    <measurement group_id="O2" value="1.19" spread="0.09"/>
                    <measurement group_id="O3" value="1.6" spread="0.3"/>
                    <measurement group_id="O4" value="1.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 day 5,multiple dose LCZ696 400 mg Q.D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.4"/>
                    <measurement group_id="O2" value="0.9" spread="0.2"/>
                    <measurement group_id="O3" value="1.3" spread="0.6"/>
                    <measurement group_id="O4" value="1.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Clearance From Plasma (CLr) After Multiple Dose Administration (Day 5)</title>
        <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
        <time_frame>Day 5</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Mild Renal Impaired Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impaired Matched Healthy Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impaired Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Moderate Renal Impaired Matched Healthy Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance From Plasma (CLr) After Multiple Dose Administration (Day 5)</title>
          <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
          <population>FAS</population>
          <units>mL/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHU377 day 5,multiple dose of LCZ696 400 mg Q.D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2" spread="30.5"/>
                    <measurement group_id="O2" value="129.1" spread="97.0"/>
                    <measurement group_id="O3" value="48.9" spread="36.3"/>
                    <measurement group_id="O4" value="143.9" spread="145.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657 day 5, multiple dose of LCZ696 400 mg Q.D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.1" spread="99.0"/>
                    <measurement group_id="O2" value="499.0" spread="251.3"/>
                    <measurement group_id="O3" value="111.0" spread="81.4"/>
                    <measurement group_id="O4" value="486.0" spread="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 day 5,multiple dose LCZ696 400 mg Q.D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.6" spread="84.7"/>
                    <measurement group_id="O2" value="313.8" spread="144.5"/>
                    <measurement group_id="O3" value="73.2" spread="43.1"/>
                    <measurement group_id="O4" value="317.0" spread="109.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount of Drug Excreted Into the Urine From Time Zero to 24-hours Post-dose (Ae0-24) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)</title>
        <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
        <time_frame>Day 1 and Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mild Renal Impaired Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impaired Matched Healthy Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impaired Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Moderate Renal Impaired Matched Healthy Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Drug Excreted Into the Urine From Time Zero to 24-hours Post-dose (Ae0-24) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)</title>
          <description>Blood samples will be collected for the determination of plasma concentrations of VAL489 (valsartan), AHU377( Sacubitril) and LBQ657 (a human metabolite of sacubitril)</description>
          <units>ug</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHU377 day 1, single dose of LCZ696 400 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360.2" spread="99.1"/>
                    <measurement group_id="O2" value="1560" spread="1294"/>
                    <measurement group_id="O3" value="419.4" spread="351.1"/>
                    <measurement group_id="O4" value="2083" spread="2496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AHU377 day 5, multiple dose of LCZ696 400 mg Q.D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="426.2" spread="120.3"/>
                    <measurement group_id="O2" value="734.5" spread="662.8"/>
                    <measurement group_id="O3" value="316.8" spread="362.9"/>
                    <measurement group_id="O4" value="790.8" spread="872.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657 day 1, single dose of LCZ696 400 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52687" spread="17107"/>
                    <measurement group_id="O2" value="68397" spread="17535"/>
                    <measurement group_id="O3" value="29653" spread="11767"/>
                    <measurement group_id="O4" value="75699" spread="15612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657 day 5, multiple dose of LCZ696 400 mg Q.D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87768" spread="21278"/>
                    <measurement group_id="O2" value="83254" spread="35800"/>
                    <measurement group_id="O3" value="43952" spread="20678"/>
                    <measurement group_id="O4" value="92113" spread="22572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 day 1, single dose of LCZ696 400 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7206" spread="3082"/>
                    <measurement group_id="O2" value="13792" spread="5250"/>
                    <measurement group_id="O3" value="4156" spread="2634"/>
                    <measurement group_id="O4" value="16902" spread="4628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 day 5,multiple dose LCZ696 400 mg Q.D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6849" spread="3852"/>
                    <measurement group_id="O2" value="11625" spread="6186"/>
                    <measurement group_id="O3" value="3713" spread="1843"/>
                    <measurement group_id="O4" value="16385" spread="8260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean 24-hours Sodium Clearance From Baseline to Day 7</title>
        <description>Sodium clearance will be measured in urine from baseline until Day 7</description>
        <time_frame>From baseline to Day 7</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Mild Renal Impaired Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impaired Matched Healthy Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impaired Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Moderate Renal Impaired Matched Healthy Subjects</title>
            <description>LCZ696 400 mg once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean 24-hours Sodium Clearance From Baseline to Day 7</title>
          <description>Sodium clearance will be measured in urine from baseline until Day 7</description>
          <population>FAS</population>
          <units>mmol/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.13" spread="51.709"/>
                    <measurement group_id="O2" value="150.25" spread="50.349"/>
                    <measurement group_id="O3" value="110.65" spread="40.169"/>
                    <measurement group_id="O4" value="158.38" spread="56.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.24" spread="36.293"/>
                    <measurement group_id="O2" value="185.75" spread="38.592"/>
                    <measurement group_id="O3" value="129.26" spread="36.510"/>
                    <measurement group_id="O4" value="196.13" spread="51.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.4" spread="48.036"/>
                    <measurement group_id="O2" value="134.88" spread="46.603"/>
                    <measurement group_id="O3" value="95.63" spread="37.799"/>
                    <measurement group_id="O4" value="134.38" spread="38.774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.38" spread="51.798"/>
                    <measurement group_id="O2" value="127.50" spread="56.488"/>
                    <measurement group_id="O3" value="97.89" spread="29.745"/>
                    <measurement group_id="O4" value="141.00" spread="43.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.70" spread="52.127"/>
                    <measurement group_id="O2" value="133.38" spread="60.656"/>
                    <measurement group_id="O3" value="107.38" spread="43.007"/>
                    <measurement group_id="O4" value="142.88" spread="40.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.68" spread="80.545"/>
                    <measurement group_id="O2" value="133.50" spread="53.596"/>
                    <measurement group_id="O3" value="104.45" spread="34.775"/>
                    <measurement group_id="O4" value="178.00" spread="44.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.32" spread="13.81"/>
                    <measurement group_id="O2" value="129.38" spread="65.600"/>
                    <measurement group_id="O3" value="106.42" spread="25.427"/>
                    <measurement group_id="O4" value="184.25" spread="81.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.63" spread="72.63"/>
                    <measurement group_id="O2" value="117.50" spread="48.794"/>
                    <measurement group_id="O3" value="102.02" spread="45.256"/>
                    <measurement group_id="O4" value="146.25" spread="69.405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LCZ696 400 mg - Mild - Renal Impaired Patients</title>
          <description>LCZ696 400 mg - Mild - Renal impaired patients</description>
        </group>
        <group group_id="E2">
          <title>LCZ696 400 mg - Mild - Matched Healthy Subjects</title>
          <description>LCZ696 400 mg - Mild - Matched healthy subjects</description>
        </group>
        <group group_id="E3">
          <title>LCZ696 400 mg - Moderate - Renal Impaired Patients</title>
          <description>LCZ696 400 mg - Moderate - Renal impaired patients</description>
        </group>
        <group group_id="E4">
          <title>LCZ696 400 mg - Moderate - Matched Healthy Subjects</title>
          <description>LCZ696 400 mg - Moderate - Matched healthy subjects</description>
        </group>
        <group group_id="E5">
          <title>LCZ696 400 mg - All Healthy Subjects</title>
          <description>LCZ696 400 mg - All healthy subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Postural orthostatic tachycardia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Diastolic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Orthostatic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

